189 related articles for article (PubMed ID: 36648168)
21. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
22. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
[TBL] [Abstract][Full Text] [Related]
23. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
[TBL] [Abstract][Full Text] [Related]
25. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
[TBL] [Abstract][Full Text] [Related]
26. Multivariable stratification of PI-RADS version 2.1 categories for the risk of false-positive target biopsy: Impact on prostate biopsy decisions.
Girometti R; Giannarini G; De Martino M; Caregnato E; Cereser L; Soligo M; Rozze D; Pizzolitto S; Isola M; Zuiani C
Eur J Radiol; 2023 Aug; 165():110897. PubMed ID: 37300933
[TBL] [Abstract][Full Text] [Related]
27. Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
Oderda M; Albisinni S; Benamran D; Calleris G; Ciccariello M; Dematteis A; Diamand R; Descotes JL; Fiard G; Forte V; Giacobbe A; Marquis A; Marra G; Messas A; Muto G; Peltier A; Rius L; Simone G; Roumeguere T; Faletti R; Gontero P
Prostate; 2023 Feb; 83(2):162-168. PubMed ID: 36259316
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic accuracy of
Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
[TBL] [Abstract][Full Text] [Related]
29. The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies.
Görtz M; Radtke JP; Hatiboglu G; Schütz V; Tosev G; Güttlein M; Leichsenring J; Stenzinger A; Bonekamp D; Schlemmer HP; Hohenfellner M; Nyarangi-Dix JN
Eur Urol Focus; 2021 Mar; 7(2):325-331. PubMed ID: 31839564
[TBL] [Abstract][Full Text] [Related]
30. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
Beksac AT; Ratnani P; Dovey Z; Parekh S; Falagario U; Roshandel R; Sobotka S; Kewlani D; Davis A; Weil R; Bashorun H; Jambor I; Lewis S; Haines K; Tewari AK
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1492. PubMed ID: 34931468
[TBL] [Abstract][Full Text] [Related]
31. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Qiu S; Liu ZH; Yang L; Wei Q
Asian J Androl; 2023; 25(4):492-498. PubMed ID: 36571328
[TBL] [Abstract][Full Text] [Related]
32. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
33. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
Hansen NL; Barrett T; Koo B; Doble A; Gnanapragasam V; Warren A; Kastner C; Bratt O
BJU Int; 2017 May; 119(5):724-730. PubMed ID: 27488931
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
Girometti R; Giannarini G; Panebianco V; Maresca S; Cereser L; De Martino M; Pizzolitto S; Pecoraro M; Ficarra V; Zuiani C; Valotto C
Br J Radiol; 2022 Mar; 95(1131):20210886. PubMed ID: 34762506
[TBL] [Abstract][Full Text] [Related]
35. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
[TBL] [Abstract][Full Text] [Related]
36. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
37. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU
Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412
[TBL] [Abstract][Full Text] [Related]
38. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
Falagario UG; Martini A; Wajswol E; Treacy PJ; Ratnani P; Jambor I; Anastos H; Lewis S; Haines K; Cormio L; Carrieri G; Rastinehad AR; Wiklund P; Tewari A
Eur Urol Oncol; 2020 Oct; 3(5):700-704. PubMed ID: 31548130
[TBL] [Abstract][Full Text] [Related]
39. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
40. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
Nguyen TA; Fourcade A; Zambon A; Saout K; Deruelle C; Joulin V; Tissot V; Doucet L; Rozet F; Fournier G; Valeri A
Urol Oncol; 2023 Aug; 41(8):354.e11-354.e18. PubMed ID: 37391283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]